Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B round brings in $48.5mm for Concert Pharmaceuticals

Executive Summary

Concert Pharmaceuticals (developing therapeutics for cancer, diabetes, and cardiovascular conditions) has closed its $48.5mm Series B venture round. Lead investor Flagship Ventures was joined by fellow new backers Brookside Capital Partners and New Leaf Venture Partners as well as current shareholders Three Arch Partners, TVM Capital, Skyline Ventures, Greylock Partners, and QVT Fund. A representative from Flagship will take a seat on the company's board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies